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Abstract
Context: Transsphenoidal neurosurgery is the accepted first-line treatment of acromegaly in the majority of patients.
Previous studies addressing preoperative somatostatin analog (SSA) treatment and subsequent surgical cure rates are
conflicting, reporting either benefits or no significant differences.
Objective: The aim of this study, based on a meta-analysis of all published reports, was to investigate whether treatment
with SSA before surgery improves the surgical outcome of acromegaly.
Data Sources: All studies of preoperative treatment of acromegaly with SSA were systematically reviewed up to December
2011. We searched the Medline, Embase, Cochrane and Google Scholar electronic databases. Study Selection: The primary
endpoint was the biochemical postoperative cure rate. We identified 286 studies, out of which 10 studies (3.49%) fulfilling
the eligibility criteria were selected for analysis; five retrospective studies with a control group, two prospective non-
randomized trials, and three prospective controlled trials. The meta-analysis was conducted using the random-effects
model.
Data Extraction: Data were extracted from published reports by two independent observers. Data Synthesis: A borderline
effect was detected in the analysis of all of the trials with control groups, with a pooled odds ratio (OR) for biochemical cure
with SSA treatment of 1.62 (95% CI, 0.93–2.82). In the analysis of the three prospective controlled trials, a statistically
significant effect was idenfified OR: 3.62 (95% CI, 1.88–6.96).
Conclusions: Preoperative treatment with SSA og GH-secreting pituitary adenomas shows a significant improvement on
surgical results. This meta-analysis suggests that in centers without optimal results all patients with a GH-secreting pituitary
macroadenoma should be treated with a long-acting SSA prior to surgical treatment.
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Introduction
Acromegaly is a rare but severe endocrine disease due to excess
GH production, caused by a pituitary adenoma in the vast
majority of cases (around 98%). The incidence of acromegaly is
approximately 5 cases per million per year and the prevalence is
60 cases per million [1]. The diagnosis is often preceded by around
10 years of active but unrecognized disease [2]. Somatotroph
adenomas are monoclonal in origin and develop as a result of
genetic changes. Over 90% of patients with acromegaly have
benign monoclonal pituitary adenomas, which are not surrounded
by hyperplasic tissue [3]. Other contributors that could facilitate
the expansion of the somatotroph tumor cells are hypothalamic
GHRH or somatostatin, paracrine growth factors and ghrelin
[2,4]. Recent data suggest the importance of the role of ghrelin in
the pathophysiological regulation of GH [5–7]. Current treatment
for acromegaly includes neurosurgery, radiotherapy and medical
therapy with dopamine agonists, somatostatin analog (SSA), and
the GH-receptor antagonist pegvisomant [2,8–10].
Transsphenoidal neurosurgery is the accepted first-line treat-
ment of acromegaly in the majority of patients. Outcome
predictors include tumour size, extrasellar extension, cavernous
sinus or dural invasion, pretreatment GH and IGF-I levels and
surgical expertise [11,12]. The best reported cure rates for
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microadenomas and macroadenomas are 80–90% and 50–60%
respectively [11–14]. In the Belgian registry of acromegaly,
a survey of ‘‘real life’’ outcome in 418 acromegalic subjects, the
cure rate of surgery by the definition of both normal IGF for age
and GH ,2 mg/l was 34% [15]. Overall cure rates as low as 18%
(39% microadenomas and 12% macroadenomas) have been
reported [16]. It is possible that other studies with low cure rates
remain unpublished.
Primary or secondary medical treatment of acromegaly with
somatostatin analog (SSA) can lead to relief of symptoms [17] and
normalized GH and IGF-I [18]. SSA treatment may cause
shrinkage of GH-secreting pituitary adenomas [18,19]. Theoret-
ically, this could improve the likelihood of a radical resection.
Furthermore, it has been suggested that SSA treatment softens the
tumor parenchyma and thereby facilitates tumor removal [20,21].
It has also been reported that SSA pretreatment leads to
a shortening of postoperative hospital stay [22].
Previous studies addressing preoperative SSA treatment and
subsequent surgical cure rates are conflicting, reporting benefit
[21–24] or no difference with preoperative SSA treatment [20,25–
29]. In recent guidelines, a role for presurgical medical therapy
with SSA to improve biochemical outcomes with surgery has been
suggested, although further studies are needed to support general
use [30]. Moreover, there is currently insufficient evidence to
recommend it for improved surgical outcome or postoperative
complications [31].
The aim of this study, based on meta-analysis of all published
reports, was to investigate whether treatment with somatostatin
analogs before surgery improves the surgical outcome of
acromegaly.
Materials and Methods
Identification of Relevant Articles
All studies on the preoperative treatment of acromegaly with
somatostatin analogs were systematically reviewed up to Decem-
ber 2011 (key words: acromegaly AND preoperative AND
somatostatin analogs AND (octreotide OR lanreotide). The search
strategy was unrestricted. We included studies investigating the
effect of preoperative somatostatin analogs treatment on post-
operative cure rates, searching the Medline, Embase, Cochrane
and Google Scholar electronic databases. With the aim of
identifying additional candidate studies, we reviewed the reference
list of the eligible primary studies, narrative reviews and systematic
reviews. In cases where multiple publications existed from the
same study, the article with the most information was included.
We identified 286 studies; we then exclude studies that were not
original, studies that did not report outcomes of interest, studies
whose full text could not be obtained, and studies with insufficient
data for meta-analysis. We also excluded studies that did not
report the surgical outcome or measure IGF-I. We identified
twenty-one studies: eleven prospective or retrospective studies
without a control group [32–42], five retrospective studies with
a control group [20–22,27,28], two non-randomized prospective
studies with control group [25,26] and three randomized pro-
spective controlled trials [23,24,29]. A summary of the follow-up
strategy used to identify the studies is shown in Figure S1. The
studies without a control group were excluded from meta-analysis,
as a result of which only 10 studies were finally selected (Table S1).
Data Extraction
Data were extracted from published reports by two independent
observers (FPG and FC). Discrepancies were resolved by
discussion among the authors of this report. The following data
were extracted: description of study characteristics, age, gender
distribution, number of patients included, postoperative bio-
chemical remission criteria as defined in the different studies
(main objective, age adjusted normal IGF-I, fasting GH and GH
after oral glucose tolerance test, Table S1), type and dose of
somatostatin analog, preoperative medical treatment duration,
time of postoperative evaluation, adenoma size (micro-or macro-
adenoma), postoperative complications, the effect of treatment on
tumor size. The studies were generally of good quality, with few
losses to follow-up and the use of appropriate statistical methods.
Statistical Analysis
The results are expressed as the mean (SD), median and range,
absolute values and percentage. The main outcome of interest was
the percentage of postoperative biochemical cure rate. The odds
ratio (OR) was used as a measure of association, with its 95%
confidence interval. Statistical heterogeneity was assessed using
Galbraith and L’Abbe´ plots, and the Q statistic from DerSimonian
and Laird. The meta-analysis was conducted using the random-
effects model, because of the marked clinical heterogeneity. The
possibility of publication bias was assessed using a funnel plot.
Funnel plot asymmetry was evaluated by Begg’s and Egger’s tests,
and a significant publication bias was considered if the P value was
,0.05. A sensitivity analysis was also carried out by evaluating the
influence of the absence of each individual study on the global
measure of association. Furthermore, a subgroup analysis was
performed including the three randomized prospective controlled
trials.
Data were analyzed by EPIDAT 3.1 software (Xunta de
Galicia/PHO, A Corun˜a, Galicia, Spain, 2006). All reported p-
values are two sided, with significance set at p,0.05.
Results
Meta-analysis was first performed using all of the studies with
a control group (n= 10) and then with randomized prospective
controlled trials (n = 3).
All Identified Trials with Control Group (n = 10)
The characteristics of the retrospective or prospective studies
with a control group (n= 10) are shown in table 1. Participants in
the trials tend to be middle-aged men or women; the mean age
range was 40.6–47.5 years, with a percentage range for females of
40–54%. The number of patients in each trial ranged from 24 in
the study by Kristoff et al [25] to 286 in the study by Losa et al
[28].
The type of SSA used in most of the studies was short acting
octreotide (table S1). In the most recent studies-Shen et al [29] and
the Carlsen et al trial [23]-octreotide LAR was used, 20 mg im
every 28th day for 3 months and 20 mg im every 28th day for 6
months, respectively. In the Losa et al study [28] several SSA were
utilized, and in the study of Mao et al [24] lanreotide SL was used,
starting with 30 mg/2 weeks im and increasing to 30 mg/week im
at week 8 if mean GH.2.5 mg/l on GH day curves. The duration
of preoperative treatment was variable, with a mean range
between 5.8 to 36 weeks. The postsurgical evaluation time varied
from 1 week (with short acting SSA) to more than 24 weeks.
Several methodological problems were identified: five of the
studies [20–22,27,28] were retrospective, with short acting
octreotide. The study by Biersmaz et al [26] was a prospective
non-randomized study with a reduced sample size. On the other
hand, the SSA was short acting and pretreatment IGF-I values
were higher in the treated group than in the control group.
Preoperative Treatment of Acromegaly
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Differences in cure rates between treatment groups in the
included studies are detailed in table S2. The cure rate was higher
in the treatment group in the studies by Stevenaert et al [21],
Colao et al [22], Plockinger et al [27], Carlsen et al [23], Mao
et al [24] and Shen et al [29]. A statistically significant effect was
detected in the studies of Stevenaert et al [21] and Mao et al. [24].
Figure S2a shows the effect of SSA pretreatment on biochemical
cure rate in all of the trials with a control group. The treatment
shows a borderline significant effect, with a pooled OR (random
effects) for biochemical cure of 1.62 (95% CI, 0.93–2.82). Similar
results were obtained after a sensitivity analysis was performed
(Table S3). This analysis determines the overall effect (global OR)
after removal of the meta-analysis of each of the individual studies.
This analysis shows that the probability of cure is higher in the
treatment group than in the control group, even though no
statistical significance was achieved.
Surgical outcome in published studies varies greatly. We
analyzed if there was a relationship between untreated surgical
outcome and SSA pretreatment results. Regression analysis of the
cured percentage in untreated patients versus the odds ratio of the
ten studies analyzed and presented in table S2, revealed a highly
significant linear relationship (Spearman Rho=20.842, adjusted
R2= 0.806, P,0.0001) indicating that centers with good surgical
results do not benefit from pretreatment and centers with worse
surgical results benefit most from pretreatment. (Figure S3).
Tumor Shrinkage, Hospital Stay and Surgical
Complications
The mean volume reduction in the treated group was evaluated
in several studies. It varied from 40% in the study of Kristoff et al
[25] to 25% in the trial of Plockinger et al [27]. Colao et al [22]
found a shorter hospital stay in the treated group versus control
group (5.660.5 vs 8.660.7 days), whereas Biersmaz et al [26]
found no difference (8.268 vs 7.167). The surgical complications
evaluated prospectively in the studies by Carlsen et al [23] and
Mao et al [24] found no difference between treated and control
groups.
Randomized Prospective Controlled Trials (n = 3)
When only the three randomized prospective controlled trials
[23,24,29] were analyzed, the following results were found. The
differences in cure rates between treatment groups in the
prospective trials are detailed in figure S2b. The treatment effect
was significant, with a pooled OR (random effects) for biochemical
cure with SSA treatment of 3.62 (95% CI, 1.88–6.96).
Publication Bias
We examined the funnel plot for signs of publication bias
(Figure S4). No asymmetry or small-study effects were detected,
and the Begg’s and Egger’s tests were not statistically significant
(P.0.05).
Discussion
This systematic review and meta-analysis refines the place of
treatment with somatostatin analog before surgery in the surgical
outcome of acromegaly. Based on biochemical cure and only
including prospective randomized trials, preoperative treatment
with somatostatin analog of GH-secreting pituitary adenomas
shows a significant improvement on the surgical results, with an
odds ratio (random effects) of 3.62 (95% CI, 1.88–6.96). We have
found a highly significant relationship between untreated surgical
outcome and SSA pretreatment results. These data indicate that
centers with good surgical results do not benefit from pretreatment
and centers with worse surgical results benefit most from
pretreatment.
Transsphenoidal neurosurgery is the accepted first-line treat-
ment of acromegaly in the majority of patients. Even if it is not
curative, surgical debulking of pituitary macroadenomas causing
acromegaly improves control by SSA [43,44]. The outcome of
treatment with somatostatin analogs as primary or secondary
therapy in clinical practice has been recently reviewed by Colao
et al [8], controlling excess GH in 60–62% of patients with
normalization of IGF-I levels in 59–49% of patients. Tumor
shrinkage, evaluated as a reduction of at least 20% compared to
the baseline, was observed in 56–75% of patients treated with
somatostatin analogs. SSA efficacy is high, and only around 25%
of the patients have a poor response or resistance, when
considering biochemical and tumoral effects jointly [8]. A recent
meta-analysis on the effects of octreotide on tumor mass in
acromegaly has found that octreotide LAR induces clinically
relevant tumor shrinkage in more than half of patients with
acromegaly, and that intramuscular octreotide LAR produced
tumor shrinkage in twice as many patients as subcutaneous
octreotide [45]. These data suggest a possible explanation for the
improved results with long-acting SSA when compared to studies
with subcutaneous octreotide. The results of the present study are
mainly based on prospective studies in patients with macroade-
noma [23,24,29], and should probably not be applied to
microadenoma patients. In the study by Carlsen et al [23],
presurgical treatment did not improve surgical results in micro-
adenoma patients. The SSA doses employed in the three
prospective controlled trials were for octreotide LAR 20 mg im
every 28th day and for lanreotide SL up to 30 mg/week
im.Theoretically it could be possible that higher SSA doses
improve the surgical outcome, although there are no studies
analyzing SSA pretreatment with different doses. There are data
indicating that high SSA doses could increase its affinity for
somatostatin receptor 5 or induce an up regulation of somatostatin
receptor 2 or alter its degradation [46].
There are some clinical data which suggest that the main reason
for the improved surgical outcome in the treated group was that
drug pretreatment made some of the tumors less invasive [29].
However, other mechanisms that could modify the biology of the
GH-secreting pituitary tumor cannot be excluded; recent studies
have found that somatostatin analogs pretreatment modulate aryl
hydrocarbon receptor interacting protein in somatotroph adeno-
mas [47]. We believe that the present results are very important
for the treatment of acromegaly, in real clinical practice. Outside
of international reference centers, the surgical cure of acromegaly
is low [15,16] or largely unknown; any clinical intervention
capable of improving surgical results should be greatly appreci-
ated. Regression analysis of the cured percentage in untreated
patients versus the odds ratio of the pretreatment effect on the ten
studies analyzed, revealed a highly significant linear relationship
(Spearman Rho=20.842, adjusted R2= 0.806, P,0.0001).
When we compare the outcome of the preoperative treatment
in the prospective randomized studies with the retrospective
studies, the results are clearly better in the former. These results
could be due to the fact that, from a clinical practice perspective,
there should probably be a tendency to treat preoperatively
patients with more biochemically active acromegaly, with greater
GH and IGF-I. Patients with more biochemically active
acromegaly have a worse prognosis for postoperative cure
[8,11,12]. Moreover, in some prospective studies with a control
group, the treated group had a greater IGF-I than the control
group [26].
Preoperative Treatment of Acromegaly
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We analyzed the possibility of publication bias (when only the
positive results are published) using a funnel plot (Figure S4). No
asymmetry or small-study effects were detected, suggesting the
absence of publication bias.
We could not conduct a specific meta-analysis for adenomas
considered to be non-resectable due to a lack of information in
most of the articles reviewed. Some studies suggest that presurgical
treatment did not improve the results in macroadenomas
considered to be non-resectable [20]. We lack sufficient data to
analyze the length of hospital stay or surgical complication rates.
The most recent prospective randomized trials did not observe any
difference in hospital stay or surgical complication rates between
preoperative SSA treatment or not [23,24,29].
This study has several limitations. The first is the small
number of studies available. To overcome this limitation, we
decided to pool the prospective and retrospective studies. In this
analysis, although there was a clear trend towards an
improvement in the cure rate, the results show a positive
borderline significant effect. However, when we only analyzed
prospective randomized control studies (n = 3), we found
a clearly significant improvement in the surgical cure with
SSA pretreatment. The second limitation is the length of the
postoperative evaluation period. An ideal period could be 1 year
after SSA withdrawal, in order to exclude any lingering effect of
presurgical SSA treatment on the outcome [48]. However,
when considering the prospective randomized trials, the
evaluation in the study by Carlsen et al [23] was performed 3
months postoperatively, and in the study by Mao et al and
Shen et al [24,29] at least 4 months postoperatively, both
intervals considered as a ‘‘safe’’ period to allow for washout of
SSA effects [48,49].
In conclusion, the present meta-analysis suggests that in centers
without optimal surgical results all patients with a GH-secreting
pituitary macroadenoma should be treated with a long-acting
somatostatin analog prior to surgical treatment.
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